Switching between covered GLP-1s
Short answer: You can switch among Wegovy, Zepbound (KwikPen), and Foundayo within the Bridge — all three cost the same $50 — with your prescriber's updated authorization. The main costs of switching are clinical, not financial: titration restarts with the new molecule, which means a month or two back at adaptation doses.
Program facts last verified against CMS: July 21, 2026
When switching makes sense — and when patience does
Good reasons to switch: persistent intolerable side effects after a fair trial, a plateau your prescriber thinks the other molecule might break (the tirzepatide efficacy edge in trial averages is real), or sustained supply problems with your current product. Weaker reasons: slow first-month results (early doses are adaptation doses — effects build through the middle of titration) or single missed-stock incidents a pharmacy transfer would solve.
Mechanics: your prescriber submits the change, the new drug starts at its own low dose, and each monthly fill remains $50. Remember the form rule changes with the drug — switching to Zepbound means KwikPen, explicitly, on the prescription.
Take the 2-minute eligibility check →
Common questions
Will I lose ground during a switch?
Some patients hold steady through the transition; some regain slightly during the new titration's early weeks. Your prescriber can sequence the change to minimize the gap.
Does a switch cost anything extra?
No — it's the same $50 per fill on the new drug. The cost is time spent back at sub-maintenance doses.
How many switches does the program allow?
No published cap — it's governed by clinical reasonableness and your prescriber's willingness to document the rationale.
Related
Program-fact sources: CMS — Medicare GLP-1 Bridge · KFF